Investors initially celebrated a mixed Q2 earnings report from Valeant Pharmaceuticals Intl Inc VRX 0.46% to the tune of a 7 percent Tuesday-morning pop for the stock. However, that enthusiasm quickly evaporated as the reality of yet another guidance cut and an uncertain future started to sink in.
After finishing Tuesday’s session up just 1.7 percent, Valeant’s slide spilled over into a 10.6 percent sell-off on Wednesday.
According to a pair of Wall Street analysts, Valeant investors are right to be skeptical, and the company has a long way to go before it has put its troubles in the rear-view mirror.
Turnaround Not Here Yet
According to Rodman & Renshaw analyst Raghuram Selvaraju, traders don’t have to look any further than the latest guidance cut to see Valeant isn’t in recovery mode quite yet.
“While we remain confident in Valeant’s ability to manage its debt position and continue to stabilize the business, we nevertheless believe that—especially in light of the revenue guidance cut—the evidence of a turnaround is still not sufficient for us to turn bullish on the stock,” Selvaraju wrote on Wednesday.
Expect More Guidance Cuts
Canaccord Genuity analyst Neil Maruka echoed Selvaraju’s sentiment. Maruka said Valeant investors should expect more guidance cuts over the next four quarters.
“The delayed genericization of several products including Mephyton, Syprine, and Isuprel have partially offset the negative impact of divestitures; however, this generic competition is nonetheless expected before the end of the year and we believe is likely to result in the erosion of ~$300 million in annualized revenue in 2018,” Maruka wrote.
For now, both Canaccord and Rodman & Renshaw are staying…
Click here to continue reading
Want to learn more about how to profit off the stock market? Or maybe you just want to be able to look sophisticated in front of your coworkers when they ask you what you are reading on your Kindle, and you’d prefer to tell them “Oh, I’m just reading a book about stock market analysis,” rather than the usual “Oh, I’m just looking at pics of my ex-girlfriend on Facebook.” For these reasons and more, check out my book, Beating Wall Street with Common Sense. I don’t have a degree in finance; I have a degree in neuroscience. You don’t have to predict what stocks will do if you can predict what traders will do and be one step ahead of them. I made a 400% return in the stock market over five years using only basic principles of psychology and common sense. Beating Wall Street with Common Sense is now available on Amazon, and tradingcommonsense.com is always available on your local internet!
